Publications & Abstracts

  • Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors.
    Tsimberidou A.M., Beer P., Bendall J., Dow J., King J., McElwaine-Johnn H. and Wistuba I.I.
    Abstract CT151. American Association for Cancer Research Virtual Annual Meeting I; April 27-28 2020.

  • Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma.
    Nastoupil L.J., Neelapu S.S., Davis E., Samaniego F., Fowler N.H., Westin J.R., Lee H.J., Wang M., Hagemeister F.B., Cecil A.R.L., Dow J., McHale D., Silva F., Ward P., Yavari A., Shuttleworth S.J.; and Beer P.
    Abstract 4099. 61st American Society of Hematology Annual Meeting and Exposition; December 7-10 2019; Orlando, Florida (FL), USA

  • Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy
    David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins
    JCI Insight 2018, 3(11), e120631